DR. DIANA C MEDGYESY MD
Prescription History 1083660708
Internal Medicine - Medical Oncology in Fort Collins, CO

NPI Status: Active since May 25, 2006

Contact Information

2121 E HARMONY RD
SUITE 170
FORT COLLINS, CO
ZIP 80528
Phone: (970) 493-6337
Fax: (970) 493-3528

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DIANA C MEDGYESY MD, an active Medical Oncology specialist practicing in Fort Collins, CO. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 394 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 169 claims alone.


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 26
30-Day Fills 72.9
Days Supply 2,188
CO State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills103.6
Peer Average Days Supply3,080
Conservative Utilization

This provider writes prescriptions for this formulation 39.5% less frequently than the standard regional baseline metric for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $316.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.17

State Avg Cost Per Claim

$14.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 169
30-Day Fills 475.6
Days Supply 14,219
CO State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills153.2
Peer Average Days Supply4,573
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 177.0% higher than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,326.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.51

State Avg Cost Per Claim

$29.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Exemestane

Generic Formulation: ExemestaneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 51.4
Days Supply 1,520
CO State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills58.5
Peer Average Days Supply1,736
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,041.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$335.64

State Avg Cost Per Claim

$246.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 35.0
Days Supply 1,050
CO State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills114.5
Peer Average Days Supply3,349
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.4% less volume than the regional standard for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $241.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.19

State Avg Cost Per Claim

$25.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Ibrance

Generic Formulation: PalbociclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 560
CO State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.7
Peer Average Days Supply691
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $345,077.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,253.88

State Avg Cost Per Claim

$14,599.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 72
30-Day Fills 195.2
Days Supply 5,841
CO State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills116.5
Peer Average Days Supply3,484
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 46.9% more claims than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,060.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.61

State Avg Cost Per Claim

$33.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Potassium Chloride

Generic Formulation: Potassium ChlorideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 38.0
Days Supply 1,140
CO State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills90.1
Peer Average Days Supply2,607
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.6% less volume than the regional standard for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $295.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.08

State Avg Cost Per Claim

$31.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.

Therapeutic Applications

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. A normal level of potassium in the blood is important. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Most people get enough potassium by eating a well-balanced diet. Some conditions that can lower your body's potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with water pills/diuretics.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 39
30-Day Fills 97.3
Days Supply 2,915
CO State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills77.9
Peer Average Days Supply2,323
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,050.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.93

State Avg Cost Per Claim

$38.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 31.0
Days Supply 930
CO State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills63.1
Peer Average Days Supply1,771
Conservative Utilization

This provider writes prescriptions for this formulation 45.7% less frequently than the standard regional baseline metric for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,865.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$940.28

State Avg Cost Per Claim

$905.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DIANA C MEDGYESY MD provides transparency into local medical care patterns within Fort Collins, CO.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.